Stock CRVS CORVUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Market Closed - Nasdaq
Other stock markets
 01:30:00 29/06/2024 am IST 		5-day change 1st Jan Change
1.82 USD -2.67% Intraday chart for Corvus Pharmaceuticals, Inc. +2.25% +3.41%
07/05 Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing MT
07/05 Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $8 From $7, Maintains Outperform Rating MT

Evolution of the average Target Price on Corvus Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

2.IMCApi5uPnnpUYZPQkUrK8a0Hc7fwIiyVqzDB6FNMGk.EJDD4VoLDxG2Yr4iEhNjf6nncpeesOvWNJWRRv4XARNwhs3Sa1xhO6hi5Q~1fcd1427eeaaf14236cfdc5cccc2068f

Analyst Recommendations on Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing MT
Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $8 From $7, Maintains Outperform Rating MT
Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating MT
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating MT
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating MT
Oppenheimer Initiates Coverage on Corvus Pharmaceuticals With Outperform Rating, $7 Price Target MT
Ladenburg Thalmann Adjusts Corvus Pharmaceuticals Price Target to $10 From $4, Maintains Buy Rating MT
Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $4 From $2, Maintains Overweight Rating MT
Ladenburg Thalmann Starts Corvus Pharmaceuticals at Buy with $2 Price Target MT
Cantor Fitzgerald Adjusts Corvus Pharmaceuticals' Price Target to $4 from $8, Keeps Overweight Rating MT
Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $8 From $5, Maintains Overweight Rating MT
Jefferies Reinstates Corvus Pharmaceuticals at Buy With $8 Price Target MT
CORVUS PHARMACEUTICALS : Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $5 From $10, Maintains Overweight Rating MT
CORVUS PHARMACEUTICALS : Mizuho Securities Adjusts Corvus Pharmaceuticals' Price Target to $3.50 From $4, Maintains Neutral Rating MT
CORVUS PHARMACEUTICALS : HC Wainwright Adjusts Corvus Pharmaceuticals' Price Target to $6 from $9.50, Keeps Buy Rating MT
CORVUS PHARMACEUTICALS : Cantor Fitzgerald Starts Corvus Pharmaceuticals With Overweight Rating, $10 Price Target MT
CORVUS PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Corvus Pharmaceuticals to $9.50 From $12, Maintains Buy Rating MT
CORVUS PHARMACEUTICALS : Mizuho Downgrades Corvus Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $4 From $7 MT
CORVUS PHARMACEUTICALS : Wedbush Adjusts Price Target on Corvus Pharmaceuticals to $6 From $8, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.82 USD
Average target price
7.833 USD
Spread / Average Target
+330.40%
High Price Target
12 USD
Spread / Highest target
+559.34%
Low Price Target
3.5 USD
Spread / Lowest Target
+92.31%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Corvus Pharmaceuticals, Inc.

Oppenheimer
Ladenburg Thalmann
Cantor Fitzgerald
Jefferies & Co.
Mizuho Securities
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CRVS Stock
  4. Consensus Corvus Pharmaceuticals, Inc.